3 May 2024 in Science Immunology
Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory “checkpoint molecules,” such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell–intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6 + T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor–treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell–dependent immune checkpoint that regulates human T cell function.
5 March 2024 in The Pediatric Infectious Disease Journal
The European Society for Clinical Microbiology and Infectious Diseases recommends 3rd generation cephalosporins and metronidazole for empirical treatment of community-acquired brain abscesses. In 53 retrospectively analyzed pediatric patients with community-acquired brain abscesses at a German University Hospital Staphylococcus aureus was identified as a relevant pathogen (21%). Therefore, it may be reasonable to cover S. aureus when selecting empirical therapy.
1 January 1991 in Theriogenology
1 October 2020 in Gynecologic Oncology
1 February 2005 in International Journal of Gynecological Cancer
15 July 2004 in Journal of Clinical Oncology
5052 Background: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant syndrome that confers a 60–80% lifetime risk of developing colorectal cancer and a 40–60% lifetime risk of developing endometrial cancer. Large population-based studies have shown that women with colon cancer who do not meet Amsterdam criteria for HNPCC but have a first-degree relative with colon cancer also have a significant increased relative risk (RR 9.4) for developing endometrial cancer. The purpose of this study was to evaluate the characteristics of patients with both colorectal and endometrial cancer in order to identify subgroups who may benefit from early cancer screening. Methods: Between 1985–2002, 77 patients with both colorectal and endometrial cancer were identified. Clinical and pathologic information was obtained from medical records. Patients were divided into three groups: AC+ (met Amsterdam criteria for HNPCC), AC-R (family history of at least one HNPCC-related cancer), and AC- (no family history of HNPCC-related cancers). Results: Eight patients were assigned to the AC+ group, 27 patients to the AC-R group, and 41 patients to the AC- group. The mean age at diagnosis of the first cancer for each group was 44, 58, and 58 years. The median interval of time between the two cancer diagnoses was 4.7, 3.0, and 8.1 years for each group. Sixteen percent of patients (12/77) developed both colorectal and endometrial cancer within one year. Forty-eight percent of patients (37/77) had colorectal cancer and 36% (28/77) had endometrial cancer as their initial cancer diagnosis. Conclusions: In this cohort of women with both colorectal and endometrial cancer, only 10% met Amsterdam criteria for HNPCC. Thirty-five percent did not meet Amsterdam criteria but had at least one relative with an HNPCC-related cancer. In this group (AC-R), 63% of patients developed their second cancer within 5 years of their initial cancer diagnosis. On-going studies are being performed to identify whether molecular markers in combination with family history can be used to identify women at risk for developing second cancers. No significant financial relationships to disclose.